8-K: Beyond Air Q2 Revenue Jumps 128%, Secures $32M Financing

Beyond Air, Inc. announced fiscal second quarter 2026 financial results, reporting a 128% year-over-year revenue increase to $1.8 million and securing $32 million in new financing.

Summary

• Revenue for the fiscal second quarter ended September 30, 2025, increased 128% year-over-year to $1.8 million, driven by increased demand for LungFit PH in the U.S. and international expansion.
• Net loss attributable to common stockholders significantly decreased to $7.9 million, or $1.25 per share, compared to $13.4 million, or $5.67 per share, in the prior year's quarter.
• The company secured up to $32 million in new capital, including a $12.0 million promissory note and an equity line of credit for up to $20 million, extending its cash runway into calendar 2027.
• Robert (Bob) Goodman, a Beyond Air Board member, was appointed Interim Chief Commercial Officer, replacing David Webster.
• Beyond Air achieved Medical Device Single Audit Program (MDSAP) certification, demonstrating conformity with regulatory requirements in Australia, Brazil, Canada, European Union, Japan, and the United States.
• A PMA supplement for the second-generation LungFit PH was submitted to the U.S. FDA in June 2025, with anticipated approval and launch before the end of calendar 2026.
• The U.S. Patent and Trademark Office granted a design patent allowance for the second-generation LungFit PH through 2040.
• Updated fiscal year 2026 revenue guidance to $8 $10 million.
• Progress was made in clinical development, including the completion of Part A of the Phase 1a trial for the Beyond Cancer solid tumor program, with median overall survival expected to exceed 23 months.
• The U.S. FDA granted Orphan Drug Designation to BA-101 for Glioblastoma (GBM) and BA-102 for Phelan-McDermid Syndrome (PMS), with BA-102 expected to enter Phase 1 clinical trials by the end of 2026.

Sentiment

Score: 8

Explanation: The filing indicates strong positive momentum with significant revenue growth, substantial reduction in net loss, successful capital raise extending financial runway, key regulatory progress for its flagship product, and advancements in its clinical pipeline. These factors collectively point to a very positive outlook despite the company still operating at a net loss.

Positives

• Revenue increased by 128% year-over-year to $1.8 million for the fiscal quarter ended September 30, 2025.
• Net loss attributable to common stockholders decreased significantly to $7.9 million from $13.4 million in the prior year's quarter.
• Gross loss decreased to $0.3 million from $1.1 million in the prior year, primarily due to sales growth.
• Research and development expenses decreased by $2.1 million to $2.5 million.
• Selling, general and administrative expenses decreased by $2.3 million to $4.9 million.
• Secured up to $32 million in new capital, including a $12.0 million debt agreement with no payments due for the first year, extending cash runway into calendar 2027.
• Appointed experienced Board member Bob Goodman as Interim Chief Commercial Officer to lead commercial strategy.
• Achieved Medical Device Single Audit Program (MDSAP) certification, facilitating international regulatory compliance.
• PMA supplement for the second-generation LungFit PH submitted to the FDA, with anticipated approval and launch before the end of calendar 2026.
• U.S. Patent and Trademark Office granted a design patent allowance for the second-generation LungFit PH through 2040.
• Expanded global LungFit PH distribution network to 35 countries, covering 2.8 billion people.
• FDA granted Orphan Drug Designation for BA-101 (Glioblastoma) and BA-102 (Phelan-McDermid Syndrome), accelerating development pathways.

Negatives

• The company continues to report a net loss of $7.9 million for the quarter.
• A gross loss of $0.3 million was recognized, despite a decrease from the prior year.
• David Webster, the previous Chief Commercial Officer, departed the company.

Risks

• The ability to raise additional capital may be challenging.
• The timing and results of future pre-clinical studies and clinical trials are uncertain.
• Regulatory authorities, including the FDA, may delay or not grant approval for product candidates.
• The approach to discover and develop novel drugs is unproven and may not lead to efficacious or marketable products.
• The ability to fund and the results of further pre-clinical studies and clinical trials of product candidates are not guaranteed.
• Obtaining, maintaining, and protecting intellectual property utilized by products is critical and may face challenges.
• Competition from others using similar technology and developing products for similar uses could impact market share.
• Dependence on collaborators for development and commercialization efforts poses risks.

Future Outlook

Beyond Air updated its fiscal year 2026 revenue guidance to $8 $10 million. The company anticipates FDA approval and subsequent launch of its second-generation LungFit PH before the end of calendar 2026, subject to regulatory review. International submissions for LungFit PH are on track. In its NeuroNOS program, BA-102 is expected to progress to a Phase 1 first-in-human clinical trial by the end of 2026, with data potentially available in 2027. The recent capital infusion is expected to provide a cash runway into calendar 2027.

Management Comments

• "Over the past year, we have made steady progress deploying LungFit PH to hospitals across the U.S. and establishing a global distribution network."
• "As the first and only FDA-approved tankless nitric oxide generator and delivery system that uses ambient air to produce nitric oxide on demand for hospital use, LungFit PH is delivering meaningful workflow and efficiency benefits for clinicians and hospital administrators."
• "With the recent capital infusion, we plan to accelerate commercial execution and advance regulatory initiatives, including select international submissions and our second-generation LungFit PH."
• "We also welcome Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer to lead our commercial strategy and team transitioning from David Webster, who leaves us with our gratitude."
• "We are gearing up for regulatory approvals outside the US as well as the anticipated FDA approval of our second generation LungFit PH and subsequent launch before the end of calendar 2026, subject to regulatory review and clearance."

Industry Context

Beyond Air operates in the specialized medical device and biopharmaceutical sectors, focusing on nitric oxide (NO) applications. Its LungFit PH system addresses persistent pulmonary hypertension of the newborn (PPHN), a critical condition, by offering a tankless NO delivery system that aims to improve hospital efficiency and safety. The company's pipeline extends into oncology (Beyond Cancer) and neurological disorders (NeuroNOS), targeting solid tumors, Glioblastoma, and Phelan-McDermid Syndrome, indicating a strategy to leverage NO's therapeutic potential across diverse, high-unmet-need areas. The expansion of its global distribution network and achievement of MDSAP certification are crucial steps for a medical device company seeking international market penetration and regulatory harmonization.

Management Changes

Related Party Transactions

• An additional $2.1 million related to an insider loan was recorded as long-term liabilities pending finalization of terms.

Stakeholder Impact

• Shareholders: Potential for future value creation due to strong revenue growth, reduced losses, extended cash runway, and pipeline advancements, but also potential dilution from the equity line of credit.
• Employees: Team expansion is anticipated under the new Interim Chief Commercial Officer, indicating potential growth opportunities.
• Customers (Hospitals/Clinicians): Continued deployment of LungFit PH and anticipated launch of the second-generation system offer improved workflow and efficiency benefits.
• Patients: Progress in clinical trials for Beyond Cancer and NeuroNOS programs, along with Orphan Drug Designations, offer hope for new treatments for severe conditions like solid tumors, Glioblastoma, and Phelan-McDermid Syndrome.
• Creditors: Streeterville Capital, LLC provided $12.0 million in debt financing, with no payments due for the first 12 months, indicating a structured repayment plan.

Next Steps

• Accelerate commercial execution and advance regulatory initiatives, including select international submissions and the second-generation LungFit PH.
• Attend the AARC Annual Congress from December 6th to 8th in Phoenix, AZ.
• Anticipated FDA approval and launch of the second-generation LungFit PH before the end of calendar 2026.
• Progress BA-102 to a Phase 1 first-in-human clinical trial by the end of 2026, with data expected in 2027.
• Continue clinical development for the Beyond Cancer solid tumor program, including the Phase 1b trial.

Key Dates

Recommendation

Beyond Air's fiscal Q2 2026 results demonstrate significant operational and financial improvements, including a 128% year-over-year revenue increase and a substantial reduction in net loss. The successful securing of $32 million in new capital extends the company's cash runway into 2027, mitigating near-term liquidity concerns. Strategic advancements, such as the appointment of an experienced Interim CCO, MDSAP certification, and the anticipated FDA approval of the second-generation LungFit PH, position the company for continued commercial growth. Furthermore, progress in its Beyond Cancer and NeuroNOS clinical programs, including Orphan Drug Designations, highlights a robust and diversified pipeline. While the company remains unprofitable, the strong positive momentum across commercial, financial, and R&D fronts makes it an attractive 'buy' for growth-oriented investors willing to accept the inherent risks of a development-stage biopharmaceutical and medical device company.

Keywords

Beyond Air, XAIR, LungFit PH, Nitric Oxide, Medical Device, Biopharmaceutical, Financial Results, Q2 2026, Revenue Growth, Debt Financing, Orphan Drug Designation, Glioblastoma, Phelan-McDermid Syndrome, Solid Tumors, Autism Spectrum Disorder, FDA Approval, MDSAP Certification, Clinical Trials